Two other studies investigated the effect of HDACi Entinostat with PD-L1 inhibitors, Atezolizumab in breast cancer patients (NCT02708680, ENCORE 602, TRIO025) and Avelumab in ovarian cancer patients (NCT02915523). This evidence concerns the gene CD274 and breast carcinoma.